A Phase II, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) Patients
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2016
At a glance
- Drugs Oshadi D (Primary) ; Oshadi R (Primary) ; Cytarabine; Mitoxantrone
- Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia
- Focus Therapeutic Use
- 28 Mar 2016 Planned End Date changed from 1 Jun 2017 to 1 Dec 2018 as per ClinicalTrials.gov record.
- 28 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2018 as per ClinicalTrials.gov record.
- 28 Mar 2016 Planned initiation date changed from 1 Jul 2015 to 1 Jan 2017 as per ClinicalTrials.gov record.